{
    "clinical_study": {
        "@rank": "15218", 
        "brief_summary": {
            "textblock": "A clinical study to determine the efficacy and safety of MK0869 in the treatment of\n      depression"
        }, 
        "brief_title": "Treatment of Patients With Major Depressive Disorder With MK0869 (0869-059)(COMPLETED)", 
        "completion_date": {
            "#text": "March 2004", 
            "@type": "Actual"
        }, 
        "condition": "Major Depressive Disorder", 
        "condition_browse": {
            "mesh_term": [
                "Depressive Disorder", 
                "Depression", 
                "Depressive Disorder, Major"
            ]
        }, 
        "detailed_description": {
            "textblock": "The duration of treatment is 8 weeks."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Major Depressive Disorder"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": "450", 
        "firstreceived_date": "May 2, 2002", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00035009", 
            "org_study_id": "2006_402", 
            "secondary_id": [
                "Formally-1A407", 
                "MK0869-059"
            ]
        }, 
        "intervention": [
            {
                "intervention_name": "MK0869, aprepitant", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "Comparator: paroxetine HCL", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Paroxetine", 
                "Aprepitant"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "March 15, 2011", 
        "official_title": "A Double-Blind, Multicenter, Placebo- and Active-Controlled Acute and Extension Study of MK0869 in the Treatment of Patients With Major Depressive Disorder With Melancholic Features", 
        "overall_official": {
            "affiliation": "Merck Sharp & Dohme Corp.", 
            "last_name": "Medical Monitor", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 3", 
        "primary_outcome": {
            "measure": "Change from baseline in HAMD-17 total score at week 8. Mk-0869 will be generally well tolerated"
        }, 
        "reference": [
            {
                "PMID": "16248986", 
                "citation": "Keller M, Montgomery S, Ball W, Morrison M, Snavely D, Liu G, Hargreaves R, Hietala J, Lines C, Beebe K, Reines S. Lack of Efficacy of the Substance P (Neurokinin(1) Receptor) Antagonist Aprepitant in the Treatment of Major Depressive Disorder. Biol Psychiatry. 2005 Oct 21; [Epub ahead of print]"
            }, 
            {
                "PMID": "17825841", 
                "citation": "Liu KS, Snavely DB, Ball WA, Lines CR, Reines SA, Potter WZ. Is bigger better for depression trials? J Psychiatr Res. 2008 Jul;42(8):622-30. Epub 2007 Sep 7."
            }
        ], 
        "removed_countries": {
            "country": "United States"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00035009"
        }, 
        "responsible_party": {
            "name_title": "Vice President, Late Stage Development Group Leader", 
            "organization": "Merck Sharp & Dohme Corp"
        }, 
        "secondary_outcome": {
            "measure": "Actual CGI-I score at week 8,  improving social disability by change from baseline in Sheehan Disability Score at Week 8, change from baseline in the HAMA score at week 8, change from baseline in depressed mood of the HAMD-17 at week 8"
        }, 
        "source": "Merck Sharp & Dohme Corp.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Merck Sharp & Dohme Corp.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2001", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2011"
    }, 
    "geocoordinates": {}
}